COVID-19 TestingNCT04757298
Optimization of a New Adaptive Intervention to Increase COVID-19 Testing
A study testing Navigation Services, Critical Dialogue and Brief Counseling in people with COVID-19 Testing, run by University of Illinois at Urbana-Champaign at 1 site in United States.
Trial summary
This study tests an adaptation of the HIV Continuum of Prevention, Care, and Treatment Framework (CoPCT) for use in tracking COVID-19 testing and follow-up in a medically and socially vulnerable population. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- COVID-19 Testing
- What is being tested?
- Navigation Services, Critical Dialogue and Brief Counseling
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 668 participants
- Where
- 1 siteUnited States
- Study dates
- 12 Feb 2021to 25 Oct 2022
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- over 18 years of age
- having high risk to contract COVID or develop related complications
- able to speak English
- able and willing to provide informed consent.
Who cannot join
- under 18 years of age
- not at high risk to contract COVID or develop related complications
- unable to speak English
- unable and unwilling to provide informed consent
Trial locations and contacts
1 site in 1 country.
United States1 site
North Jersey Community Research Initiative
Newark, New Jersey, 07102
About this study
Official title: Optimization of a New Adaptive Intervention to Increase COVID-19 Testing Among People at High Risk in an Urban Community
This study tests an adaptation of the HIV Continuum of Prevention, Care, and Treatment Framework (CoPCT) for use in tracking COVID-19 testing and follow-up in a medically and socially vulnerable population. This study uses an integrated research collaborative framework that facilitates dialogue among researchers, community members, and service providers as a tool for optimizing the adaptive intervention and will take place at the North Jersey Community Research Initiative (NJCRI)
Read the detailed description
This study will use the Multiphase Optimization Strategy (MOST) to optimize an adaptive intervention that successfully navigates COVID-19 medically or socially vulnerable people through a continuum of prevention, care and treatment (CoPCT) modeled on the HIV CoPCT. The COVID-19 CoPCT starts with testing and continues with successful adherence to prevention or treatment guidelines to help prevent and/or treat COVID-19. The study will assess the effectiveness of Navigation Services compared to referrals in increasing COVID-19 testing and Brief Counseling in increasing adherence to the State of NJ recommendations for COVID-19 prevention and treatment. The study will also examine the effect of Critical Dialogue on testing behavior among people who decline to be tested for COVID-19. The investigators will develop decision rules about what evidence-based-interventions work best for what types of people (e.g., those who test right away, versus decliners) and in what period of the COVID-19 continuum. Finally, the study will shed light on factors associated with testing and adherence to NJ recommendations. Investigators will follow Community Based Participatory Research principles in implementing a sequential, multiple assignment randomized trial (SMART) design. Adjusting for possible 15% loss to follow-up, a total sample of 670 people who are medically and socially vulnerable to infection and poor outcomes with COVID-19 will be enrolled as the intent-to treat-sample. The investigators are confident that they can recruit this sample in Essex County, NJ based on their previous experience and because the parent study research team has established relationships with other service agencies in the community from which, in addition to NJCRI, research participants will be drawn. The primary outcome is completion of the COVID-19 test within one week of the first intervention session The study will include 3 stages in which participants will be randomized to one of two possible interventions as follows:
- Eligible and consenting participants will be randomized to receive the first-stage intervention: Navigation Services (NS) or standard services (referral to testing and NJ digital information brochure after testing). The primary outcome is completion of the COVID-19 test within one week of the intervention session.
- Those who get tested will be randomized to receive the second-stage intervention: continue with NS or standard treatment or switch to Brief Counseling (BC). The outcome will be adherence to NJ recommendations. For those testing positive, adherence means engaging in a 14-day quarantine, receiving medical care as needed and contact tracing. For those testing negative, adherence means social distancing and wearing masks.
- Those who do not get tested will be randomized into their second-stage intervention to continue with NS or digital brochure or switch to Critical Dialogue (CD). The outcome will be completing COVID-19 testing within 1 week of the second stage intervention session. Those who complete the testing will then be randomized to either continue with NS or digital brochure or switch to BC. Those who do not get tested will be randomized to continued NS or digital brochure or switch to CD. The outcome will be adherence to NJ recommendations, as defined above. All variables will be measured using standardized measures selected from the National Institutes of Health (NIH) PhenX Toolkit.
For the primary aim of comparing effects of Navigation Services versus referral on testing behavior and NJ recommendations adherence, using standard sample size formula for difference of two proportions, a total sample size of 582 subjects is needed to have 80% power at α=0.05 to detect a 10% difference in proportions, assuming 70% in the referral group will complete testing and adhere to specific NJ recommendations. The 582 sample size has 85% to detect a difference of 15% in adherence rates to NJ recommendations between two interventions.
- Conditions
- COVID-19 Testing
- Being tested
- Navigation Services, Critical Dialogue, Brief Counseling, Referral and Digital Brochure
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Navigation ServicesBehavioural
Navigation services include assessment and support with service referrals. Each participant will meet with a peer navigator in person or on Zoom Conferencing for 30 minutes to go over results from their social and health needs assessment that is retrieved from the baseline assessment. The navigator shares information about COVID-19, answers questions about testing, and makes referrals to other needed services
Critical DialogueBehavioural
Critical Dialogue includes three one-hour-long, open-group-sessions facilitated in person or online by a trained licensed facilitator. Group critical dialogue is prompted by thematic images developed by the NCCB to foster a deeper understanding of how systematic stigma, feelings of rage as victims of discrimination, and/or apathy may impact participants' beliefs and behaviors related to COVID-19 and empower participants to make critical choices to protect their health and the health of their communities.
Brief CounselingBehavioural
Brief Counseling is a 15-minute post-COVID-19 test session delivered by a trained licensed clinician in person or via Zoom Conferencing. In the session, the clinician shares the test results and offers recommendations and information about COVID-19 treatment and prevention.
Referral and Digital BrochureBehavioural
Referral will consist of a five-minute phone call where an outreach worker offers participants information about COVID-19 testing and encourages them to get tested within one week. A digital brochure containing NJ recommendations is e-mailed or texted to participants.
| Study group | Role | What they receive |
|---|---|---|
| Navigation only | Other | Participants are randomized to receive navigation services only. Receives: Behavioral: Navigation Services |
| Navigation + Brief Counseling | Other | After initial randomization into NS, some participants are randomized to receive Brief Counseling (BC) Receives: Behavioral: Navigation Services; Behavioral: Brief Counseling |
| Navigation + Critical Dialogue | Other | After initial randomization into NS, some participants are randomized to receive Critical Dialogue (CD) Receives: Behavioral: Navigation Services; Behavioral: Critical Dialogue |
| Brochure only | Other | Participants are randomized to receive Brochure only. Receives: Behavioral: Referral and Digital Brochure |
| Brochure + Brief Counseling | Other | After initial randomization to receive a brochure, some participants are randomized to receive Brief Counseling (BC) Receives: Behavioral: Brief Counseling; Behavioral: Referral and Digital Brochure |
| Brochure + Critical Dialogue | Other | After initial randomization to receive a brochure, some participants are randomized to receive Critical Dialogue (CD) Receives: Behavioral: Critical Dialogue; Behavioral: Referral and Digital Brochure |
What is being measured
The primary outcome is the main question the study is designed to answer.
Stage 1: Completion of COVID-19 Test After First Randomization
For the first stage intervention, the primary outcome is coming to the agency and completing the COVID-19 antigen test one week after completing the baseline.
Measured: Stage 1: Within one week of completing baseline.
Stage 2: Reported COVID Test in Last 30 Days at 6 Months Post Baseline
For the second stage intervention, the primary outcome is self-reported completion of COVID-19 test in the past 30 days at the follow up completed 6 months after baseline. Study participants were asked whether they had completed a COVID-19 test in the past 30 days.
Measured: Stage 2: 6 months post baseline (4th follow up visit)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Feb 2021
- Study start12 Feb 2021
- Primary completion25 Oct 2022
- Study completion25 Oct 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for COVID-19 TestingStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Sequential
- Model description
- SMART Design
- Masking
- None (open label)
- Enrolment
- 668 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Illinois at Urbana-Champaign
- Sponsor type
- University, hospital or other
- Collaborators
- North Jersey Community Research Initiative, National Institute on Minority Health and Health Disparities (NIMHD), University of Michigan
- Responsible party
- Principal investigator, Liliane Cambraia Windsor, University of Illinois at Urbana-Champaign
- Investigators
- Liliane Windsor, PhD, Principal investigator, University of Illinois Urbana Champaign
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04757298
- Sponsor's protocol ID
- UIUC-NJCRI 102497-18274-267805
- Other IDs
- 3R01MD010629-04S2
- Status last verified
- Feb 2024
- First submitted
- 15 Feb 2021
- Last updated
- 15 Feb 2024
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: De-identified data can be shared upon request for research purposes and under a data sharing agreement.
Publications
Lee CA, Gamino D, Lore M, Donelson C, Windsor LC. Use of research electronic data capture (REDCap) in a sequential multiple assignment randomized trial (SMART): a practical example of automating double randomization. BMC Med Res Methodol. 2023 Jul 6;23(1):162. doi: 10.1186/s12874-023-01986-6.
PubMed 37415099Lee CA, Gamino D, Lore M, Donelson C, Windsor LC. Use of research electronic data capture (REDCap) in a sequential multiple assignment randomized trial (SMART): A practical example of automating double randomization. Res Sq [Preprint]. 2023 Feb 24:rs.3.rs-2573133. doi: 10.21203/rs.3.rs-2573133/v1.
PubMed 36865151Windsor L, Benoit E, M Pinto R, Sarol J. Optimization of a new adaptive intervention using the SMART Design to increase COVID-19 testing among people at high risk in an urban community. Trials. 2022 Apr 14;23(1):310. doi: 10.1186/s13063-022-06216-w.
PubMed 35421999
Study at a glance
From the registry record, last updated by the sponsor on 15 Feb 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Optimization of a New Adaptive Intervention to Increase COVID-19 Testing Among People at High Risk in an Urban Community
- ClinicalTrials.gov ID
- NCT04757298
- Acronym / sponsor ID
- UIUC-NJCRI 102497-18274-267805
- Conditions
- COVID-19 Testing
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 668 participants (actual)
- Lead sponsor
- University of Illinois at Urbana-ChampaignUniversity, hospital or other
- Collaborators
- North Jersey Community Research Initiative, National Institute on Minority Health and Health Disparities (NIMHD), University of Michigan
- Study start
- 12 Feb 2021 (actual)
- Primary completion
- 25 Oct 2022 (actual)
- Study completion
- 25 Oct 2022 (actual)
- First posted
- 17 Feb 2021 (actual)
- Results
- Posted 15 Feb 2024
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study tests an adaptation of the HIV Continuum of Prevention, Care, and Treatment Framework (CoPCT) for use in tracking COVID-19 testing and follow-up in a medically and socially vulnerable population. This study uses an integrated research collaborative framework that facilitates dialogue among researchers, community members, and service providers as a tool for optimizing the adaptive intervention and will take place at the North Jersey Community Research Initiative (NJCRI)
Detailed description
This study will use the Multiphase Optimization Strategy (MOST) to optimize an adaptive intervention that successfully navigates COVID-19 medically or socially vulnerable people through a continuum of prevention, care and treatment (CoPCT) modeled on the HIV CoPCT. The COVID-19 CoPCT starts with testing and continues with successful adherence to prevention or treatment guidelines to help prevent and/or treat COVID-19. The study will assess the effectiveness of Navigation Services compared to referrals in increasing COVID-19 testing and Brief Counseling in increasing adherence to the State of NJ recommendations for COVID-19 prevention and treatment. The study will also examine the effect of Critical Dialogue on testing behavior among people who decline to be tested for COVID-19. The investigators will develop decision rules about what evidence-based-interventions work best for what types of people (e.g., those who test right away, versus decliners) and in what period of the COVID-19 continuum. Finally, the study will shed light on factors associated with testing and adherence to NJ recommendations. Investigators will follow Community Based Participatory Research principles in implementing a sequential, multiple assignment randomized trial (SMART) design. Adjusting for possible 15% loss to follow-up, a total sample of 670 people who are medically and socially vulnerable to infection and poor outcomes with COVID-19 will be enrolled as the intent-to treat-sample. The investigators are confident that they can recruit this sample in Essex County, NJ based on their previous experience and because the parent study research team has established relationships with other service agencies in the community from which, in addition to NJCRI, research participants will be drawn. The primary outcome is completion of the COVID-19 test within one week of the first intervention session The study will include 3 stages in which participants will be randomized to one of two possible interventions as follows:
- Eligible and consenting participants will be randomized to receive the first-stage intervention: Navigation Services (NS) or standard services (referral to testing and NJ digital information brochure after testing). The primary outcome is completion of the COVID-19 test within one week of the intervention session.
- Those who get tested will be randomized to receive the second-stage intervention: continue with NS or standard treatment or switch to Brief Counseling (BC). The outcome will be adherence to NJ recommendations. For those testing positive, adherence means engaging in a 14-day quarantine, receiving medical care as needed and contact tracing. For those testing negative, adherence means social distancing and wearing masks.
- Those who do not get tested will be randomized into their second-stage intervention to continue with NS or digital brochure or switch to Critical Dialogue (CD). The outcome will be completing COVID-19 testing within 1 week of the second stage intervention session. Those who complete the testing will then be randomized to either continue with NS or digital brochure or switch to BC. Those who do not get tested will be randomized to continued NS or digital brochure or switch to CD. The outcome will be adherence to NJ recommendations, as defined above. All variables will be measured using standardized measures selected from the National Institutes of Health (NIH) PhenX Toolkit.
For the primary aim of comparing effects of Navigation Services versus referral on testing behavior and NJ recommendations adherence, using standard sample size formula for difference of two proportions, a total sample size of 582 subjects is needed to have 80% power at α=0.05 to detect a 10% difference in proportions, assuming 70% in the referral group will complete testing and adhere to specific NJ recommendations. The 582 sample size has 85% to detect a difference of 15% in adherence rates to NJ recommendations between two interventions.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Sequential
- Masking
- None (open label)
- Number of arms
- 6
- Model description
- SMART Design
| Arm | Type | Receives |
|---|---|---|
| Navigation only | Other | Behavioral: Navigation ServicesParticipants are randomized to receive navigation services only. |
| Navigation + Brief Counseling | Other | Behavioral: Navigation Services, Behavioral: Brief CounselingAfter initial randomization into NS, some participants are randomized to receive Brief Counseling (BC) |
| Navigation + Critical Dialogue | Other | Behavioral: Navigation Services, Behavioral: Critical DialogueAfter initial randomization into NS, some participants are randomized to receive Critical Dialogue (CD) |
| Brochure only | Other | Behavioral: Referral and Digital BrochureParticipants are randomized to receive Brochure only. |
| Brochure + Brief Counseling | Other | Behavioral: Brief Counseling, Behavioral: Referral and Digital BrochureAfter initial randomization to receive a brochure, some participants are randomized to receive Brief Counseling (BC) |
| Brochure + Critical Dialogue | Other | Behavioral: Critical Dialogue, Behavioral: Referral and Digital BrochureAfter initial randomization to receive a brochure, some participants are randomized to receive Critical Dialogue (CD) |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- over 18 years of age
- having high risk to contract COVID or develop related complications
- able to speak English
- able and willing to provide informed consent.
Key exclusion criteria (4 listed)
- under 18 years of age
- not at high risk to contract COVID or develop related complications
- unable to speak English
- unable and unwilling to provide informed consent
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Navigation ServicesNavigation services include assessment and support with service referrals. Each participant will meet with a peer navigator in person or on Zoom Conferencing for 30 minutes to go over results from their social and health needs assessment that is retrieved from the baseline assessment. The navigator shares information about COVID-19, answers questions about testing, and makes referrals to other needed services | Behavioural | Navigation + Brief Counseling, Navigation + Critical Dialogue, Navigation only |
| Critical DialogueCritical Dialogue includes three one-hour-long, open-group-sessions facilitated in person or online by a trained licensed facilitator. Group critical dialogue is prompted by thematic images developed by the NCCB to foster a deeper understanding of how systematic stigma, feelings of rage as victims of discrimination, and/or apathy may impact participants' beliefs and behaviors related to COVID-19 and empower participants to make critical choices to protect their health and the health of their communities. | Behavioural | Brochure + Critical Dialogue, Navigation + Critical Dialogue |
| Brief CounselingBrief Counseling is a 15-minute post-COVID-19 test session delivered by a trained licensed clinician in person or via Zoom Conferencing. In the session, the clinician shares the test results and offers recommendations and information about COVID-19 treatment and prevention. | Behavioural | Brochure + Brief Counseling, Navigation + Brief Counseling |
| Referral and Digital BrochureReferral will consist of a five-minute phone call where an outreach worker offers participants information about COVID-19 testing and encourages them to get tested within one week. A digital brochure containing NJ recommendations is e-mailed or texted to participants. | Behavioural | Brochure + Brief Counseling, Brochure + Critical Dialogue, Brochure only |
Primary outcome
Stage 1: Completion of COVID-19 Test After First Randomization
Time frame: Stage 1: Within one week of completing baseline.
For the first stage intervention, the primary outcome is coming to the agency and completing the COVID-19 antigen test one week after completing the baseline.
Stage 2: Reported COVID Test in Last 30 Days at 6 Months Post Baseline
Time frame: Stage 2: 6 months post baseline (4th follow up visit)
For the second stage intervention, the primary outcome is self-reported completion of COVID-19 test in the past 30 days at the follow up completed 6 months after baseline. Study participants were asked whether they had completed a COVID-19 test in the past 30 days.
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Feb 2024.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 37415099Lee CA, Gamino D, Lore M, Donelson C, Windsor LC. Use of research electronic data capture (REDCap) in a sequential multiple assignment randomized trial (SMART): a practical example of automating double randomization. BMC Med Res Methodol. 2023 Jul 6;23(1):162. doi: 10.1186/s12874-023-01986-6.
- Derived from this study: PubMed 36865151Lee CA, Gamino D, Lore M, Donelson C, Windsor LC. Use of research electronic data capture (REDCap) in a sequential multiple assignment randomized trial (SMART): A practical example of automating double randomization. Res Sq [Preprint]. 2023 Feb 24:rs.3.rs-2573133. doi: 10.21203/rs.3.rs-2573133/v1.
- Derived from this study: PubMed 35421999Windsor L, Benoit E, M Pinto R, Sarol J. Optimization of a new adaptive intervention using the SMART Design to increase COVID-19 testing among people at high risk in an urban community. Trials. 2022 Apr 14;23(1):310. doi: 10.1186/s13063-022-06216-w.
- Individual participant dataSharing planned: Yes. De-identified data can be shared upon request for research purposes and under a data sharing agreement.
Related trials for COVID-19 Testing
Active, not recruitingObservational study
A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza
COVID-19, Coronavirus Disease 2019
Not yet recruiting
Usability and Clinical Validation of the Flu A/B/COVID-19 + RSV Multiplex Rapid Test
SARS-CoV-2 Infection, Influenza A
Active, not recruiting
Clinical Validation of the NowFuture Digital Flu / COVID Test in Anterior Nasal Samples for Over-the-Counter (OTC) Use in Australia
SARS CoV 2 Infection, Influenza A Virus Infection
Not yet recruitingObservational study
The Precision Mito- Mito Map COMPASS Study
Mitochondrial Diseases, Myalgic Encephalomyelitis Chronic Fatigue Syndrome
RecruitingObservational study
Serological and PCR Testing for COVID-19
COVID-19
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Liliane Windsor, PhD principal investigator
University of Illinois Urbana Champaign
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Navigation Services, Critical Dialogue and Brief Counseling in people with COVID-19 Testing, run by University of Illinois at Urbana-Champaign at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 Feb 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 15 Feb 2024). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Stage 1: Completion of COVID-19 Test After First Randomization (time frame: Stage 1: Within one week of completing baseline.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04757298, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Feb 2024.